Back to homepage

Immunology

Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19

Authors: Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena V Kuntsevich, Anastasia A Troshina, Elena I Kvasova, Anton A Tikhonov, Nadezhda F Khomyakova, Francisco Harrison, Jean-François Rossi, Timothy C Hardman

This study evaluated the safety and efficacy of azoximer bromide when used in combination with standard of care treatment in patients hospitalized with COVID-19.

More▸

Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports

Authors: Ana Victoria Carro Martínez, Lydia Montolio Chiva, Montserrat Robustillo Villarino

We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis.

More▸

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Authors: Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo

Keywords: allergic rhinoconjunctivitis, antihistamines, bilastine, drug information, drug interactions, medical information services, paediatrics, safety, urticaria. Citation: Leceta A, García A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment

More▸

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Authors: Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1

More▸

The UK approach to COVID-19 vaccination: why was it so different?

Authors: Peter MB English

This commentary is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.

More▸